Kwality Pharma receives product registration for Bleomycin 15 IU In Mexico for sale and distribution
KPL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kwality Pharmaceuticals has received product registration in Mexico for Bleomycin 15 IU, an anti-cancer drug used to treat Hodgkin's lymphoma, testicular cancer, and certain squamous cell carcinomas. The company expects a business potential of around USD 1 million in the first year from this approval. Supplies are expected to commence before the end of Q2FY26. This approval strengthens the company's presence in highly regulated international markets and adds to its global oncology product portfolio.
Positive for the company as it opens a new regulated export market and adds a USD-denominated revenue stream, though the USD 1 million first-year potential is relatively modest in scale. Reinforces the company's global oncology expansion strategy.